MX2023010997A - Métodos de administración de polipéptidos de la hormona del crecimiento de acción prolongada. - Google Patents
Métodos de administración de polipéptidos de la hormona del crecimiento de acción prolongada.Info
- Publication number
- MX2023010997A MX2023010997A MX2023010997A MX2023010997A MX2023010997A MX 2023010997 A MX2023010997 A MX 2023010997A MX 2023010997 A MX2023010997 A MX 2023010997A MX 2023010997 A MX2023010997 A MX 2023010997A MX 2023010997 A MX2023010997 A MX 2023010997A
- Authority
- MX
- Mexico
- Prior art keywords
- growth hormone
- methods
- long
- acting growth
- hormone polypeptides
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 2
- 108010051696 Growth Hormone Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 2
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 2
- 239000000854 Human Growth Hormone Substances 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163504P | 2021-03-19 | 2021-03-19 | |
| US202163272417P | 2021-10-27 | 2021-10-27 | |
| PCT/US2022/020804 WO2022197961A1 (en) | 2021-03-19 | 2022-03-17 | Methods of administering long-acting growth hormone polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010997A true MX2023010997A (es) | 2023-11-28 |
Family
ID=83320806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010997A MX2023010997A (es) | 2021-03-19 | 2022-03-17 | Métodos de administración de polipéptidos de la hormona del crecimiento de acción prolongada. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240166710A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4308151A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022145646A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230171936A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022238386A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023018980A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3214273A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL305661A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023010997A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022197961A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020155990A1 (en) * | 2001-04-20 | 2002-10-24 | Renasci, Inc., D/B/A Renasci Anti-Aging Center | Method of optimizing growth hormone replacement |
| WO2009102734A1 (en) * | 2008-02-11 | 2009-08-20 | Depomed Inc. | Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form |
| US20150158926A1 (en) * | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| HUE050002T2 (hu) * | 2013-10-21 | 2020-11-30 | Opko Biologics Ltd | Hosszan ható polipeptidek és eljárás azok elõállítására és beadására |
| EP4732848A3 (en) * | 2014-11-21 | 2026-07-29 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
| KR102527180B1 (ko) * | 2014-12-10 | 2023-04-27 | 옵코 바이오로직스 리미티드 | 장기간 작용성 ctp-변형된 성장 호르몬 폴리펩타이드의 제조 방법 |
| MY184625A (en) * | 2014-12-10 | 2021-04-09 | Opko Biologics Ltd | Methods of producing long acting ctp-modified growth hormone polypeptides |
-
2022
- 2022-03-17 US US18/282,844 patent/US20240166710A1/en active Pending
- 2022-03-17 BR BR112023018980A patent/BR112023018980A2/pt unknown
- 2022-03-17 CA CA3214273A patent/CA3214273A1/en active Pending
- 2022-03-17 EP EP22772229.5A patent/EP4308151A4/en active Pending
- 2022-03-17 AU AU2022238386A patent/AU2022238386A1/en active Pending
- 2022-03-17 KR KR1020237035239A patent/KR20230171936A/ko active Pending
- 2022-03-17 IL IL305661A patent/IL305661A/en unknown
- 2022-03-17 JP JP2022042639A patent/JP2022145646A/ja active Pending
- 2022-03-17 WO PCT/US2022/020804 patent/WO2022197961A1/en not_active Ceased
- 2022-03-17 MX MX2023010997A patent/MX2023010997A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023018980A2 (pt) | 2023-12-05 |
| EP4308151A4 (en) | 2025-02-26 |
| EP4308151A1 (en) | 2024-01-24 |
| WO2022197961A1 (en) | 2022-09-22 |
| CA3214273A1 (en) | 2022-09-22 |
| KR20230171936A (ko) | 2023-12-21 |
| US20240166710A1 (en) | 2024-05-23 |
| JP2022145646A (ja) | 2022-10-04 |
| AU2022238386A1 (en) | 2023-09-14 |
| IL305661A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000049A (es) | Degradador de tirosina cinasa y mutante de bruton, composicion y aplicacion del mismo. | |
| WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
| MX2019005466A (es) | Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. | |
| de Almeida et al. | A hypothesis for the anti-inflammatory and mechanotransduction molecular mechanisms underlying acupuncture tendon healing | |
| NZ610487A (en) | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins | |
| JOP20190019B1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| MX2025011882A (es) | Metodos de tratamiento del cancer con un agonista del receptor de linfotoxina beta | |
| MX2019003751A (es) | Proteina terapeutica. | |
| MX2022009712A (es) | Tratamiento de infeccion por coronavirus con interferon lambda. | |
| MX2025009578A (es) | Regimenes y composiciones utiles para aliviar el dolor | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| MX2023006704A (es) | Composiciones dsg2 y metodos para el tratamiento de covid-19. | |
| MX2025006619A (es) | Compuestos terapeuticos | |
| UA81689C2 (ru) | Способ предоперационного лечения послеоперационной боли бупренорфином | |
| AU2014284101B2 (en) | Treating skin ulcers | |
| RU2018132694A (ru) | Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста | |
| BR112023018980A2 (pt) | Métodos de administração de polipeptídeos de hormônio de crescimento de ação prolongada | |
| Anwar et al. | Combined botulinum toxin injections and phenol nerve/motor point blocks to manage multifocal spasticity in adults | |
| BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
| ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
| MX2024005327A (es) | Composiciones y metodos de dsg2. | |
| ZA202201446B (en) | Methods of treating multifocal cancer | |
| MX2024005084A (es) | Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada. | |
| Kim et al. | The Effect of Functional Electrical Stimulation on Hemiplegic Shoulder Subluxation. | |
| WO2022240804A3 (en) | Methods of treating sickle cell disorder and related conditions |